Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Irbesartan 30mg oral powder sachets
0205052I0AAAKAK
|
Irbesartan | Irbesartan | Cardiovascular System | No data available |
|
Irbesartan 37.5mg oral powder sachets
0205052I0AAALAL
|
Irbesartan | Irbesartan | Cardiovascular System | No data available |
|
Iremia 133microgram sublingual tablets
0407020A0BYAMBX
|
Iremia | Fentanyl | Central Nervous System | No data available |
|
Iremia 267microgram sublingual tablets
0407020A0BYANBZ
|
Iremia | Fentanyl | Central Nervous System | No data available |
|
Iremia 533microgram sublingual tablets
0407020A0BYAQBY
|
Iremia | Fentanyl | Central Nervous System | No data available |
|
Iremia 67microgram sublingual tablets
0407020A0BYARCH
|
Iremia | Fentanyl | Central Nervous System | No data available |
|
Iremia 800microgram sublingual tablets
0407020A0BYASBB
|
Iremia | Fentanyl | Central Nervous System | No data available |
|
Iressa 250mg tablets
0801050AWBBAAAA
|
Iressa | Gefitinib | Malignant Disease and Immunosuppression | No data available |
|
Irinotecan 100mg/5ml solution for infusion vials
0801050Q0AAAAAA
|
Irinotecan hydrochloride | Irinotecan hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Irinotecan 300mg/15ml solution for infusion vials
0801050Q0AAACAC
|
Irinotecan hydrochloride | Irinotecan hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Irinotecan 40mg/2ml solution for infusion vials
0801050Q0AAABAB
|
Irinotecan hydrochloride | Irinotecan hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Irinotecan 500mg/25ml solution for infusion vials
0801050Q0AAADAD
|
Irinotecan hydrochloride | Irinotecan hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
Irinotecan pegylated liposomal 43mg/10ml inf vials
0801050Q0AAAEAE
|
Irinotecan hydrochloride | Irinotecan hydrochloride | Malignant Disease and Immunosuppression | No data available |
|
IroFate 125mg/ml oral drops
0901011P0BFAACJ
|
IroFate | Ferrous sulfate | Nutrition and Blood | No data available |
|
Iron sorbitol 100mg/2ml solution for injection ampoules
0901012M0AAAAAA
|
Iron sorbitol | Iron sorbitol | Nutrition and Blood | No data available |
|
Iron sucrose 100mg/5ml solution for injection ampoules
0901012I0AAAAAA
|
Iron sucrose | Iron sucrose | Nutrition and Blood | No data available |
|
Iron sucrose 50mg/2.5ml solution for injection vials
0901012I0AAACAC
|
Iron sucrose | Iron sucrose | Nutrition and Blood | No data available |
|
Ironorm capsules
0901011C0BSAAA0
|
Ironorm (Compound) | Compound iron preparations | Nutrition and Blood | No data available |
|
Irrigation belt
23705307002
|
Irrigation belt | Irrigation Washout Appliances | Stoma Appliances | No data available |
|
Irrigation disposable sleeve 40mm
23701007005
|
Irrigation disposable sleeve 40mm | Irrigation Washout Appliances | Stoma Appliances | No data available |
|
Irrigation disposable sleeve 60mm
23701007006
|
Irrigation disposable sleeve 60mm | Irrigation Washout Appliances | Stoma Appliances | No data available |
|
Isentress 100mg chewable tablets
0503010AEBBABAB
|
Isentress | Raltegravir | Infections | No data available |
|
Isentress 100mg granules for oral suspension sachets
0503010AEBBADAD
|
Isentress | Raltegravir | Infections | No data available |
|
Isentress 25mg chewable tablets
0503010AEBBACAC
|
Isentress | Raltegravir | Infections | No data available |
|
Isentress 400mg tablets
0503010AEBBAAAA
|
Isentress | Raltegravir | Infections | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.